18
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment?

      Trends in Cell Biology
      Elsevier BV

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cell division relies on the activation of cyclins, which bind to cyclin-dependent kinases (CDKs) to induce cell-cycle progression towards S phase and later to initiate mitosis. Since uncontrolled cyclin-dependent kinase activity is often the cause of human cancer, their function is tightly regulated by cell-cycle inhibitors such as the p21 and p27 Cip/Kip proteins. Following anti-mitogenic signals or DNA damage, p21 and p27 bind to cyclin-CDK complexes to inhibit their catalytic activity and induce cell-cycle arrest. Interestingly, recent discoveries suggest that p21 and p27 might have new activities that are unrelated to their function as CDK inhibitors. The identification of new targets of Cip/Kip proteins as well as evidence of Cip/Kip cytoplasmic relocalization have revealed unexpected functions for these proteins in the control of CDK activation, in the regulation of apoptosis and in transcriptional activation. This article discusses recent insights into these possible additional functions of p21 and p27.

          Related collections

          Author and article information

          Journal
          Trends in Cell Biology
          Trends in Cell Biology
          Elsevier BV
          09628924
          February 2003
          February 2003
          : 13
          : 2
          : 65-70
          Article
          10.1016/S0962-8924(02)00043-0
          12559756
          526e1b82-04d3-4e3a-bd3a-ce5ae9ce9670
          © 2003

          https://www.elsevier.com/tdm/userlicense/1.0/

          History

          Comments

          Comment on this article